Theradaptive is a privately held, clinical-stage biologics company developing protein therapeutics for spine, orthopedics, dental, and soft tissue repair and targeted therapeutics in diverse areas such as immuno-oncology. The company leverages its therapeutic delivery platform to deliver recombinant biologics to targeted areas in the body with high precision and persistence to address unmet medical needs. Our lead product OsteoAdapt™ has earned three FDA breakthrough designations, and we are the only company with FDA Breakthrough coverage in the three largest spine indications.